arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Liquidia Corp

LQDA
$90.18 ▲ +0.73 (+0.82%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome

Analytical Summary

Liquidia Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $7.9B
Dividend Yield
Revenue Growth 4158.5%
Op. Margin 46.3%
ROIC 52.7%
FCF / Share $0.57
Trailing P/E 150.3x
Price / Book 73.3x
FCF Yield 0.6%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$132.87M
↑ +4158.5%
Net Income Profit after all expenses
$52.86M
↑ +263.2%
Operating Margin Operating profit as % of sales
46.3%
↑ +115.3% 7th
FCF / Share Free cash flow per share
$0.57
↑ +560.7%
Long-Term Debt Long-term obligations
$19.88M
↑ +0.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
7
Returns
4
Cash Quality
43

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 27 quarters